Persistence and treatment-free interval in patients being prescribed biological drugs in rheumatology practices in Germany
- 52 Downloads
The goal of this study was to analyze persistence and the treatment-free interval in patients being prescribed biological drugs in rheumatology practices in Germany.
Patients who received a first prescription of biological drugs between 2008 and 2016 in 21 rheumatologists in Germany were included in this study (index date). The main outcome was the rate of persistence with biological drugs as a function of the duration of the treatment-free interval used to define discontinuation. The secondary outcomes were the duration of the treatment-free interval, the probability of restarting therapy, and their respective association with age, gender, and diagnosis (i.e., rheumatoid arthritis, ankylosing spondylitis, and psoriatic arthritis).
A total of 4925 patients were included in this study. After 5 years of follow-up, the rate of persistence was 32.6%, 51.1%, and 65.7% if discontinuation was defined as a gap of 90, 180, and 360 days respectively. The majority of patients restarted therapy between 91 and 180 days after the discontinuation date. Advanced age was associated with a decreased probability of restarting biological therapy after a treatment-free interval of at least 91 days, with odds ratios ranging from 0.34 in people aged 61–70 years to 0.66 in those aged 31–40 years (reference value: ≤ 30 years). Finally, patients over 70 and those suffering from ankylosing spondylitis had shorter treatment-free intervals compared to those 30 years or younger (adjusted difference of − 117 days) and those suffering from rheumatoid arthritis (− 48 days) respectively.
Persistence varied widely depending on the definition of discontinuation, with the majority of nonpersistent patients restarting biological therapy shortly after discontinuation.
KeywordsPersistence Treatment-free interval Biological drugs Rheumatology practices Germany Retrospective study
Compliance with ethical standards
Conflicts of interest
The authors declare that they have no conflicts of interest.
- 4.Braun J, Bollow M, Remlinger G, Eggens U, Rudwaleit M, Distler A, Sieper J (1998) Prevalence of spondylarthropathies in HLA-B27 positive and negative blood donors. Arthritis Rheum 41:58–67. https://doi.org/10.1002/1529-0131(199801)41:1<58::AID-ART8>3.0.CO;2-G CrossRefGoogle Scholar
- 5.Hense S, Luque Ramos A, Callhoff J, Albrecht K, Zink A, Hoffmann F (2016) Prevalence of rheumatoid arthritis in Germany based on health insurance data : regional differences and first results of the PROCLAIR study. Z Rheumatol 75:819–827. https://doi.org/10.1007/s00393-016-0088-0 CrossRefGoogle Scholar
- 7.Reich K, Krüger K, Mössner R, Augustin M (2009) Epidemiology and clinical pattern of psoriatic arthritis in Germany: a prospective interdisciplinary epidemiological study of 1511 patients with plaque-type psoriasis. Br J Dermatol 160:1040–1047. https://doi.org/10.1111/j.1365-2133.2008.09023.x CrossRefGoogle Scholar
- 8.Braun J, Kellner H, Max R, Rihl M, Schmitz-Bortz E, Schulze-Koops H, Zinke S, Fan T, Ding Q, Lyu R (2013) Disease severity, quality of life, and productivity loss among patients with ankylosing spondylitis in Germany. In ACR Meeting Abstracts. https://acrabstracts.org/abstract/disease-severity-quality-of-lifeand-productivity-loss-among-patients-with-ankylosing-spondylitis-in-germany/
- 9.Listing J, Kekow J, Manger B, Burmester G-R, Pattloch D, Zink A, Strangfeld A (2015) Mortality in rheumatoid arthritis: the impact of disease activity, treatment with glucocorticoids, TNFα inhibitors and rituximab. Ann Rheum Dis 74:415–421. https://doi.org/10.1136/annrheumdis-2013-204021 CrossRefGoogle Scholar
- 12.Rosman Z, Shoenfeld Y, Zandman-Goddard G (2013) Biologic therapy for autoimmune diseases: an update. BMC Med 11(88). https://doi.org/10.1186/1741-7015-11-88
- 13.Smolen JS, Landewé R, Bijlsma J, Burmester G, Chatzidionysiou K, Dougados M, Nam J, Ramiro S, Voshaar M, van Vollenhoven R et al (2017) EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update. Ann Rheum Dis 76:960–977. https://doi.org/10.1136/annrheumdis-2016-210715 CrossRefGoogle Scholar
- 14.Mócsai A, Kovács L, Gergely P (2014) What is the future of targeted therapy in rheumatology: biologics or small molecules? BMC Med 12(43). https://doi.org/10.1186/1741-7015-12-43
- 15.Saad AA, Ashcroft DM, Watson KD, Hyrich KL, Noyce PR, Symmons DPM (2009) British Society for Rheumatology Biologics Register: persistence with anti-tumour necrosis factor therapies in patients with psoriatic arthritis: observational study from the British Society of Rheumatology Biologics Register. Arthritis Res Ther 11:R52. https://doi.org/10.1186/ar2670 CrossRefGoogle Scholar
- 22.Degli Esposti L, Favalli EG, Sangiorgi D, Di Turi R, Farina G, Gambera M, Ravasio R (2017) Persistence, switch rates, drug consumption and costs of biological treatment of rheumatoid arthritis: an observational study in Italy. Clinicoecon Outcomes Res 9:9–17. https://doi.org/10.2147/CEOR.S108730 CrossRefGoogle Scholar
- 23.Fagerli KM, Kearsley-Fleet L, Watson KD, Packham J, Contributors Group B-R, Symmons DPM, Hyrich KL (2018) Long-term persistence of TNF-inhibitor treatment in patients with psoriatic arthritis. Data from the British Society for Rheumatology Biologics Register. RMD Open 4:e000596. https://doi.org/10.1136/rmdopen-2017-000596 CrossRefGoogle Scholar
- 24.Lee M-Y, Shin J-Y, Park S-Y, Kim D, Cha H-S, Lee E-K (2018) Persistence of biologic disease-modifying antirheumatic drugs in patients with rheumatoid arthritis: an analysis of the South Korean National Health Insurance Database. Semin Arthritis Rheum 47:485–491. https://doi.org/10.1016/j.semarthrit.2017.08.007 CrossRefGoogle Scholar
- 26.Dombrowski S, Kostev K (2017) Use of electronic medical records in the epidemiological research. Cuvillier Verlag, GöttingenGoogle Scholar
- 34.Leon L, Gomez A, Vadillo C, Pato E, Rodriguez-Rodriguez L, Jover JA, Abasolo L (2018) Severe adverse drug reactions to biological disease-modifying anti-rheumatic drugs in elderly patients with rheumatoid arthritis in clinical practice. Clin Exp Rheumatol 36:29–35 28598787Google Scholar
- 35.Lee S, Mendelsohn A, Sarnes E (2010) The burden of psoriatic arthritis: a literature review from a global health systems perspective. P T 35:680–689Google Scholar
- 36.Masuda H, Miyazaki T, Shimada K, Tamura N, Matsudaira R, Yoshihara T, Ohsaka H, Sai E, Matsumori R, Fukao K, Hiki M, Kume A, Kiyanagi T, Takasaki Y, Daida H (2014) Disease duration and severity impacts on long-term cardiovascular events in Japanese patients with rheumatoid arthritis. J Cardiol 64:366–370. https://doi.org/10.1016/j.jjcc.2014.02.018 CrossRefGoogle Scholar
- 37.Jamalyaria F, Ward MM, Assassi S, Learch TJ, Lee M, Gensler LS, Brown MA, Diekman L, Tahanan A, Rahbar MH, Weisman MH, Reveille JD (2017) Ethnicity and disease severity in ankylosing spondylitis a cross-sectional analysis of three ethnic groups. Clin Rheumatol 36:2359–2364. https://doi.org/10.1007/s10067-017-3767-6 CrossRefGoogle Scholar